Drug intelligence / Profile preview

butyl toluidine blue

Development stage: Preclinical
Modality: Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Topical

Overview

Butyl toluidine blue (BuTB) is a photosensitizer utilized in photodynamic therapy (PDT). In this therapeutic approach, BuTB is activated by light of a specific wavelength, which leads to the generation of reactive oxygen species (ROS). These ROS then induce cytotoxic effects, causing damage to target cells or microorganisms. It is currently being investigated as an adjuvant therapy for promoting periodontal healing in patients with type 2 diabetes mellitus.

Beyond the preview

Go deeper on butyl toluidine blue.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on butyl toluidine blue.

Explore the full profile